Gronghui, March 27丨According to a research report published by J.P. Morgan Chase, when restoring the minimally invasive robot-B (2252.HK) “increase holdings” rating, the target price dropped slightly from HK$60 to HK$59.9. According to the bank, the group is the only company in the world that covers five major surgical specialties, including laparoscopy, orthopedics, full vascular, natural foramen, and percutaneous surgery. The bank predicts that between 2020 and 2026, the number of laparoscopic and joint replacement surgical robots installed in China will increase rapidly by 10 to 50 times, respectively. As a leading enterprise, the company believes it will be in an advantageous position to benefit from this growing trend. The bank expects the Group's revenue to grow at a compound annual rate of 161% in the 2023-27 fiscal year, and to achieve balance of payments in 2025. After listing, the group had a strong start, was sold off, and stabilized thereafter. The bank believes that there is still room for the stock to rise further in the future. Minimally invasive robot-B is now up 2% to HK$29.05, with a total market capitalization of HK$27.8 billion.